Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Mar;63(3):439-43.
doi: 10.1038/bjc.1991.101.

c-erbB-2 oncoprotein expression in primary and advanced breast cancer

C Lovekin  1 , I O Ellis, A Locker, J F Robertson, J Bell, R Nicholson, W J Gullick, C W Elston, R W Blamey
Affiliations
Free PMC article

c-erbB-2 oncoprotein expression in primary and advanced breast cancer

C Lovekin et al. Br J Cancer. 1991 Mar.
Free PMC article

Erratum in

  • Br J Cancer 1991 Jul;64(1):202

Abstract

Immunoreactivity for c-erbB-2 oncogene product expression has been investigated in patients with breast cancer using the polyclonal antibody 21N. Three series of patients were studied, 602 presenting with primary operable cancer, 57 with stage 3 and 123 with stage 4 disease. Representative tissue sections of each primary tumour were stained using a standard immunoperoxidase technique. Invasive tumour membrane immunoreactivity was assessed and identified in 15% of patients with primary operable cancer and 20% in the advanced breast cancer group. The results demonstrate a relationship between poorer survival and oncogene expression in all three patient groups. Patients in the primary operable cancer group with membrane oncoprotein expression had a poorer outcome, 35% 10-year survival, compared with those in which membrane expression was absent, 55% 10-year survival. The median survival of patients with stage 3 disease with c-erbB-2 membrane positivity was 17 months compared to 24 months with membrane negativity. In stage 4 disease median survival with membrane expression was 8.8 months compared to 19.7 months with no membrane expression. In addition in the series of primary cancers a correlation existed between histological grade and membrane immunoreactivity. Multivariate analysis showed histological grade to be a more powerful prognostic factor than c-erbB-2 protein expression. In conclusion, this study demonstrates, in a large series of patients presenting to one centre, that c-erbB-2 protein expression is a prognostic indicator in patients with primary operable and advanced breast disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Semin Oncol. 1989 Apr;16(2):148-55 - PubMed
    1. J Clin Oncol. 1990 Jan;8(1):103-12 - PubMed
    1. Nature. 1989 May 18;339(6221):230-1 - PubMed
    1. Cell. 1989 Jul 28;58(2):287-92 - PubMed
    1. Nature. 1989 Jun 22;339(6226):587 - PubMed

Publication types